News

Features

  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today the addition of an AAV-based infantile Batten disease (CLN1) program to its Batten pipeline.

  • Following a unanimous vote by the N.C. General Assembly, N.C. Governor Pat McCrory signed Taylor’s Law, which renames the legislation that created the N.C. Advisory Council on Rare Diseases in honor of Taylor King.

  • Sharon King, president of Taylor’s Tale, delivered a keynote address during North Carolina’s first Rare Disease Legislative Day on June 7.

News Coverage